Compare MOBX & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOBX | SER |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | 46 | 13 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 19.4M |
| IPO Year | N/A | N/A |
| Metric | MOBX | SER |
|---|---|---|
| Price | $0.18 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 16.7M | 196.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $134.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $1.53 |
| 52 Week High | $1.44 | $7.92 |
| Indicator | MOBX | SER |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | 39.48 |
| Support Level | $0.17 | $1.71 |
| Resistance Level | $0.34 | $4.17 |
| Average True Range (ATR) | 0.02 | 0.19 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 49.74 | 32.06 |
Mobix Labs Inc designs, develops and sells components and systems for wireless and wired connectivity, radio frequency (RF), switching and electromagnetic interference (EMI) filtering technologies. Its wireless systems solutions include products for RF and millimeter wave (mmWave) communications, mmWave imaging, software defined radio and custom RF integrated circuits (ICs) targeting the defense, aerospace, commercial and industrial sectors. The majority of the company's revenue is derived from product sales to equipment manufacturers. Geographically, it generates the maximum revenue from the United States.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.